Part D Plan To Adjust Cost Sharing For Biosimilars Questioned By PhRMA
PhRMA suggests that treating biosimilars like generics in some cases could lead to confusion and may have little impact on cost sharing for beneficiaries.
You may also be interested in...
Rebate Pass-Through Would Lower, Not Raise, Medicare Spending – PhRMA
Biopharma manufacturers dispute predictions that passing through rebates at the point-of-sale in Medicare Part D would increase government spending. Pharmacy benefit managers argue the policy would violate the Part D statute and the Trade Secrets Act.
Part D Proposal Aims To Promote Biosimilars, Generics To Reduce Costs
Medicare Part D proposed rule would lower cost sharing for biosimilars to the level of generics for some beneficiaries, allow immediate generic substitution for plans.
Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'
Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.